Evidence map›Paper›PMID 42282762›Full record

ArticlebioRxiv : the preprint server for biology2026

The hypertrophic cardiomyopathy mutation G768R makes cardiac myosin a high duty ratio motor.

Divya Pathak, Tugba N Ozturk, Aminah Dawood, Matthew C Childers, Michael Regnier, James A Spudich, Chao Liu, Kathleen M Ruppel

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Divya PathakDepartment of Biochemistry, Stanford University, Stanford, CA, USA.
Tugba N OzturkBiosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA, USA.
Aminah DawoodDepartment of Biochemistry, Stanford University, Stanford, CA, USA.ORCID 0009-0007-5095-1989
Matthew C ChildersDepartment of Bioengineering, University of Washington, Seattle, WA, USA.
Michael RegnierDepartment of Bioengineering, University of Washington, Seattle, WA, USA.
James A SpudichDepartment of Biochemistry, Stanford University, Stanford, CA, USA.
Chao LiuBiosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA, USA.ORCID 0000-0003-0057-3397
Kathleen M RuppelDepartment of Biochemistry, Stanford University, Stanford, CA, USA.

Funding

MYOSIN MOVEMENT IN VITRO: MOLECULAR CHARACTERIZATIONR01GM033289 · NIGMS · STANFORD UNIVERSITY · PI SPUDICH, JAMES · 1985 to 2024
$13.6M
From proteins to cells to tissues: A multi-scale assessment of biomechanical regulation by the myosin molecular motorRM1GM131981 · NIGMS · STANFORD UNIVERSITY · PI BERNSTEIN, DANIEL, MACK, DAVID LEE · 2019 to 2023
$10.3M
UW Center for Translational Muscle Research (Overall Application)P30AR074990 · NIAMS · UNIVERSITY OF WASHINGTON · PI MICHAEL REGNIER · 2019 to 2026
$7.5M
Computational and Experimental Models of Myosin VariantsR01HL179584 · NHLBI · UNIVERSITY OF WASHINGTON · PI Farid Moussavi-Harami, MICHAEL REGNIER · 2026 to 2026
$1.8M
Single-cell proteome heterogeneity due to MYH HCM mutations and recovery by MavacamtenR01HL180748 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI MICHAEL REGNIER, Jennifer E Van Eyk · 2026 to 2026
$741k
Shared TIRF and Patterned Illumination Fluorescence MicroscopeS10RR026775 · NCRR · STANFORD UNIVERSITY · PI STRAIGHT, AARON F · 2010 to 2010
$465k
A multiscale computational and experimental platform to investigate cardiomyopathies and targeted therapeuticsK99HL173646 · NHLBI · UNIVERSITY OF WASHINGTON · PI CHILDERS, MATTHEW CARTER · 2024 to 2025
$272k
NCRR NIH HHS S10 RR026775NHLBI NIH HHS K99 HL173646NHLBI NIH HHS R01 HL179584NHLBI NIH HHS R01 HL180748NIAMS NIH HHS P30 AR074990NIGMS NIH HHS R01 GM033289NIGMS NIH HHS RM1 GM131981
6 · The paper itself

Abstract

β-cardiac myosin is the primary motor protein in the human heart responsible for force generation by converting chemical energy from ATP hydrolysis to mechanical work. It binds actin, produces force through its powerstroke, and releases actin, and must complete this cycle several times a second within each heartbeat. Like other muscle myosins, cardiac myosin has a low duty ratio of ~5%, the fraction of time in the actin-bound force-producing state. Here we present a hypertrophic cardiomyopathy (HCM) causing mutation, G768R, that increases cardiac myosin's duty ratio to >60%, an unprecedented >10x increase unmatched by any previously studied muscle myosin mutation. In recombinantly expressed human β-cardiac myosin subfragment-1 (sS1), G768R dramatically decreases the load-sensitive actin-detachment rate and step size of single molecules measured by optical tweezers. The ~15x longer actin-bound time combined with only a modest change in overall ATPase rate predicts a duty ratio of >60%. Motility velocity is also severely slowed, as expected given the long bound time and decreased step size. All-atom molecular dynamic simulations of the pre-powerstroke and post-rigor states predict that the mutation alters lever arm priming and reduces ADP pocket opening, providing a possible structural mechanism to corroborate the experimental observations. Finally, ATPase experiments on 2-headed heavy meromyosin (HMM) constructs suggest that G768R destabilizes the autoinhibited state of myosin. Our findings of high duty ratio and reduced autoinhibition provide molecular mechanisms of cardiac hypercontractility and impaired relaxation. A muscle myosin in the heart that stays bound to actin for over half its period is bound to have significant functional and clinical consequences.

Identifiers

PMID42282762
PMCPMC13252056

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.